Francesca De Felice
Sapienza University of Rome
CancerInternal medicineRadiologySurgeryOncologyStage (cooking)Head and neck cancerInduction chemotherapyChemotherapyChemoradiotherapyDiseaseConcomitantRegimenLocally advancedIn patientCancer researchRadiation therapyColorectal cancerGeneral surgeryMedicineGastroenterology
169Publications
21H-index
1,538Citations
Publications 169
Newest
#1Claudia Marchetti (Agostino Gemelli University Polyclinic)H-Index: 2
#1Claudia MarchettiH-Index: 24
Last. Francesca De Felice (Sapienza University of Rome)H-Index: 21
view all 4 authors...
Source
#1Francesca De Felice (Sapienza University of Rome)H-Index: 21
#2Alessia Fallarino (Sapienza University of Rome)
Last. Vincenzo Tombolini (Sapienza University of Rome)H-Index: 28
view all 12 authors...
AIM To assess feasibility, complications and efficacy of induction chemotherapy followed by standard chemoradiotherapy in patients with bulky anal canal cancer. PATIENTS AND METHODS Patients with squamous cell carcinoma of the anal canal, staged bulky tumor with or without nodal involvement were prospectively enrolled. Before standard chemoradiotherapy, patients received induction chemotherapy with 3 cycles of 75 mg/m2 cisplatin and 750 mg/m2 5-fluorouracil. Patients were followed-up routinely u...
Source
#1Francesca De Felice (Sapienza University of Rome)H-Index: 21
#2Liliana Belgioia (UniGe: University of Genoa)H-Index: 11
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 14 authors...
Abstract Purpose To evaluate efficacy and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy and identify differences in clinical outcomes and severe toxicity rate. Methods PICOS/PRISMA methods were used to identify studies on PubMed, EMBASE and Cochrane Library, 2005–2019. Results Six randomized clinical trials (554 patients) were identified. Weekly cisplatin was not associated with significant overall survival (HR 1.13, 95 % CI 0.84–1.51) and progres...
Source
#1Claudia Marchetti (Agostino Gemelli University Polyclinic)H-Index: 2
#1Claudia MarchettiH-Index: 24
Last. Francesca De Felice (Sapienza University of Rome)H-Index: 21
view all 5 authors...
Phase 3 randomized clinical trials have been designed to compare secondary cytoreductive surgery followed by systemic therapy with systemic therapy alone for management of patients with recurrent ovarian cancer. This study aimed to compare differences in clinical outcomes between these two treatment approaches. The PRISMA statement was applied. Only phase 3 randomized clinical trials were included in the final analysis. Three randomized clinical trials (n = 1250 patients) were identified. Second...
1 CitationsSource
#1Francesca De Felice (Sapienza University of Rome)H-Index: 21
#2M. LeiH-Index: 7
Last. Teresa Guerrero UrbanoH-Index: 10
view all 8 authors...
Head and neck squamous cell carcinoma (HNSCC) has a significant impact on patients' quality of life and treatment can be associated with severe morbidity. Following completion of treatment, patients are followed up in order to detect potentially salvageable recurrences and to manage long-term toxicities. In recent years, a growing interest has been given to risk stratified follow-up interventions to prevent and detect recurrences and manage treatment toxicities in other tumour sites as well as t...
Source
#1Alessandra Rossetti (University of L'Aquila)H-Index: 1
#2Francesco Petragnano (University of L'Aquila)H-Index: 5
Last. Francesco Marampon (Sapienza University of Rome)H-Index: 27
view all 22 authors...
PURPOSE Herein we describe the in vitro and in vivo activity of FK228 (Romidepsin), an inhibitor of class I HDACs, in counteracting and radiosensitizing embryonal (ERMS, fusion-negative) and alveolar (ARMS, fusion-positive) rhabdomyosarcoma (RMS).METHODS RH30 (ARMS, fusion-positive) and RD (ERMS, fusion-negative) cell lines and human multipotent mesenchymal stromal cells (HMSC) were used. Flow cytometry analysis, RT-qPCR, western blotting and enzymatic assays were performed. Irradiation was deli...
Source
In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therape...
Source
#1Giuseppe Carlo Iorio (UNITO: University of Turin)H-Index: 7
#2V. Salvestrini (UniFI: University of Florence)H-Index: 3
Last. Isacco Desideri (UniFI: University of Florence)H-Index: 17
view all 9 authors...
Abstract Introduction The historically feared radiation-induced secondary cancers and cardiac toxicities observed among mediastinal classical Hodgkin Lymphoma (cHL) patients may still negatively burden the benefit of radiotherapy among long-term survivors. Modern radiotherapy (RT) delivery techniques, including intensity-modulated RT (IMRT) and deep inspiration breath-hold (DIBH) solutions, are drastically changing this scenario. Results of a literature overview are reported and discussed in thi...
Source
#1Luciana CaravattaH-Index: 14
#2Giovanna MantelloH-Index: 14
Last. Domenico GenovesiH-Index: 18
view all 33 authors...
A multi-institutional retrospective study was conducted to evaluate the pattern of care and clinical outcomes of anal cancer patients treated with intensity-modulated radiotherapy (IMRT) techniques. In a cohort of 987 patients, the clinical complete response (CR) rate (beyond 6 months) was 90.6%. The 3-year local control (LC) rate was 85.8% (95% CI: 84.4–87.2), and the 3-year colostomy-free survival (CFS) rate was 77.9% (95% CI: 76.1–79.8). Three-year progression-free survival (PFS) and overall ...
Source
#1Francesca De Felice (Sapienza University of Rome)H-Index: 21
#2Valentina Lancellotta (UCSC: Catholic University of the Sacred Heart)H-Index: 11
Last. Vitaliana De Sanctis (Sapienza University of Rome)H-Index: 20
view all 23 authors...
Purpose This systematic review focused on rare histological types of corpus uteri malignancy, including uterine carcinosarcoma (UCS), uterine clear cell carcinoma (UCCC), and uterine papillary serous carcinoma (UPSC), and it is proposed to assist with clinical decision-making. Adjuvant treatment decisions must be made based on available evidences. We mainly investigated the role of vaginal interventional radiotherapy (VIRt) in UCS, UCCC, and UPSC managements. Material and methods A systematic re...
Source